RFRachel Forbes

Rachel Forbes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rachel Forbes has a total of 220 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Deceased Donor Kidney Transplant After 10°C Static Storage

    by Mark Petrovic, Marissa Kuo, John Dubray, Rachel Forbes, Adam Miller, Peter Reese, Ciara Shaver, Matthew Bacchetta, W. Christian Crannell


  • Open Access

    Risk of Cytomegalovirus Viremia Following Transplantation of Hepatitis C‐Viremic Donor Kidneys Into Uninfected Recipients: A Multi‐Center Retrospective Cohort Study

    by Vishnu S. Potluri, David Goldberg, Siqi Zhang, Douglas E. Schaubel, Miklos Z. Molnar, Rachel Forbes, Megan E. Sise, James L. Rogers, Vasanthi Balaraman, Anshul Bhalla, et al.

    Background: Several studies have suggested an increased risk of cytomegalovirus (CMV) viremia among Hepatitis C virus (HCV)‐uninfected recipients of kidney transplants from HCV‐RNA+ deceased donors (HCV D+/R−), but these studies featured small sample sizes and limited ability to address confounding variables.Methods: We assembled a retrospective cohort of adult kidney transplant recipients at five US centers between 4/1/2015 and 12/31/2020 to determine the association between HCV D+/R− transplants and the outcomes of CMV viremia (> 1000 IU/mL), death‐censored graft failure, and mortality in the first posttransplant year compared to HCV D−/R− transplants. We generated highly similar matched cohorts of HCV D+/R− and HCV D−/R− recipients based on attributes that affect the risk of CMV viremia. We matched exactly on center, CMV donor/recipient serostatus, and antibody induction therapy.Results: The cohort comprised 275 HCV D+/R− recipients with a mean age of 52.5 years (SD = 10.7); 19% were CMV D+/R−, and 74% received anti‐thymocyte globulin induction. With variable ratio matching, 267 HCV D+/R− recipients were matched to 996 HCV D−/R− recipients. CMV viremia occurred in 15% of HCV D+/R− and 11% of HCV D−R− recipients. In Cox regression, transplantation with an HCV‐RNA+ donor kidney was not associated with a significantly higher risk of CMV viremia (HR 1.3, 95% CI 0.89–1.92) or death‐censored graft loss (HR 0.61, 95% CI 0.31–1.2).Conclusion: The risk of CMV viremia was not significantly increased among HCV D+/R− kidney recipients. Future studies should examine associations between donor‐derived HCV infection and clinical outcomes of CMV syndrome and disease.


  • Open Access

    A2/A2B to B kidney transplantation outcomes: A single center 7‐year experience

    by Alissar El Chediak, Saed Shawar, Mohammad K. Fallahzadeh, Rachel Forbes, Heidi M. Schaefer, Irene D. Feurer, Scott Rega, Jefferson L. Triozzi, David Shaffer

    Introduction: Data on long‐term outcomes following A2/A2B to B kidney transplants since the 2014 kidney allocation system (KAS) changes are few. The primary aim of this study is to report our 7‐year experience with A2/A2B to B kidney transplants and to compare post‐transplant outcomes of A2/A2B to a concurrent group of B to B kidney transplants. Additionally, the study evaluates the impact of pre‐transplant anti‐A1 titers on survival outcomes in A2/A2B transplants.Methods: This retrospective, single‐center analysis included all adults who received A2/A2B to B deceased donor kidney transplants from December 2014 to June 2021 compared to B to B recipients. The effects of pre‐transplant IgM/IgG titers, stratified as ≤1:8 and ≥1:16, on death‐censored, rejection‐free, and overall graft survival were tested.Results: Fifty‐three A2/A2B and 114 B to B adults were included with a median follow‐up time of 32 months. Overall graft survival, patient survival, and rejection‐free graft survival did not differ between the two groups. There were no differences between the groups’ overall kidney function values (p > .80) or their temporal trajectories (time by group interaction p > .11). Unadjusted death‐censored graft survival was lower in A2/A2B to B compared to B recipients (p = .03), but the effect was not significant (p = .195) after adjusting for any readmissions (p = .96), rejection episodes (p < .001) or BK infection (p = .76). We did not detect an effect of pre‐transplant titer group on death‐censored (p = .59), rejection‐free (p = .61), or overall graft survival (p = .26)Conclusions: A2/A2B to B kidney transplants have comparable overall patient and graft survival, rejection‐free graft survival, and longitudinal renal function compared to B to B transplants at our center. Allograft survival outcomes were not significantly different between patients with low and high pre‐transplant anti‐A1 IgM/IgG titers.


  • Open Access

    Generating strategies for a national comeback in pancreas transplantation: A Delphi survey and US conference report

    by Ronald F. Parsons, Krista L. Lentine, Mona Doshi, Ty B. Dunn, Rachel Forbes, Jonathan A. Fridell, Michelle T. Jesse, Martha Pavlakis, Deirdre Sawinski, Neeraj Singh, et al.


  • Open Access

    Impact of removing donation service area and region from pancreas allocation

    by Sarah E. Booker, Katrina Gauntt, Jesse Howell, Joann White, Oyedolamu Olaitan, Rachel C. Forbes


  • Twelve‐month kidney and liver outcomes of kidney transplantation from Hepatitis C Viremic deceased donors to aviremic recipients

    by Laura A. Binari, Peter Thorne, Scott A. Rega, Irene D. Feurer, Saed Shawar, Ruchi Naik, Kelly A. Birdwell, J. Harold Helderman, Anthony Langone, Bonnie Ann Sarrell, et al.

    Introduction: Utilization of hepatitis C viremic (HCV+) deceased donor kidneys (DDKT) for aviremic recipients increases opportunities for transplantation with excellent short‐term outcomes. Our primary aim was to understand longer‐term outcomes, specifically assessing kidney and liver function in the first year posttransplant.Methods: This was a retrospective single‐center study of adult DDKT recipients of HCV+ kidneys (cases) matched 1:1 to recipients of HCV‐ kidneys (comparators). Between‐group outcomes were analyzed using comparisons of means and proportions, survival analysis methods, and multivariable mixed effects models.Results: Sixty‐five cases and 65 comparators had statistically comparable demographic and clinical characteristics. There were no between‐group differences in serum creatinine or estimated glomerular filtration rate at month 12 (p = .662) or in their trajectories over months 1–12 (p > .292). Within the first 60 days, rates of liver function values >3 times upper limit of normal among cases were comparable to comparators for aspartate aminotransferase (AST) (14% vs. 6%, p = .242) and higher for alanine transaminase (ALT) (23% vs. 6%, p = .011). AST declined during the first 8 weeks (p = .005) and stabilized for both groups (p = .406) during the following 10 months. ALT declined during the first 8 weeks (p < .001), continued to decline over months 3–12 (p = .016), and the trajectory was unrelated to antiviral therapy initiation among cases.Conclusions: Aviremic recipients of HCV+ kidneys had comparable kidney outcomes to matched recipients of HCV‐ kidneys. Despite more HCV+ recipients having an elevation in ALT within the first 60 days, ALT values normalized with no identified liver complications attributed to HCV. image


  • Disparities in telemedicine utilization among kidney transplant patients during the COVID‐19 pandemic: Barriers and opportunities

    by Rachel C. Forbes, Wali R. Johnson, Nigel D'SOuza, Anthony Dreher, Scott A. Rega, Irene D. Feurer, Beatrice P. Concepcion

    Introduction: The COVID‐19 pandemic allowed for the rapid implementation of telemedicine for kidney transplant patients; however, widespread adoption may worsen existing health care inequities among vulnerable populations. This study aimed to characterize telemedicine utilization by kidney transplant patients during the early pandemic with particular attention to healthcare equity.Methods: A retrospective analysis of kidney transplant patients interacting with telemedicine was performed. Patient demographic data and distance to the transplant center were obtained. The National Center for Health Statistics (NCHS) Urban‐Rural Classification Scheme for Counties and Brokamp Neighborhood Deprivation Index (NDI) score were used to characterize patients’ counties of residence. Multivariable logistic regression evaluated associations between patient and community characteristics and the likelihood of an encounter being telemedicine.Results: This study included 1033 patients who participated in 3727 encounters from March 11 through October 2020. Characteristics associated with decreased likelihood of telemedicine use were increased age (OR = .993; 95% CI = .986‐.999, P = .022), non‐White vs. White race (OR = .826, 95% CI = .697‐.979; P = .028), male vs. female sex (OR = .746, 95% CI = .632‐.880; P < .001), and a higher Brokamp Neighborhood Deprivation Index score (OR = .159; 95% CI = .029‐.873; P = .034). The effect of distance to the transplant center on the likelihood of a telemedicine encounter differed by NCHS Urban‐Rural designation (interaction P = .018), with its likelihood increasing by 2%–3% with each 10‐mile increment among persons residing in medium‐, small‐, and non‐metropolitan counties compared to those residing in the most rural counties.Conclusions: Telemedicine visits were less often completed by patients of older age, non‐white race, male sex, and those residing in counties having higher NDI scores. While telemedicine has the potential to improve healthcare access and decrease costs, proactive efforts need to be taken to mitigate disparities in vulnerable populations.


  • Incisional Hernia Development after Live Donor Nephrectomy: Impact of Surgical Technique

    by Bernard J. DuBray, Joshua J. Thompson, David Shaffer, Doug A. Hale, Scott A. Rega, Irene D. Feurer, Rachel C. Forbes

    Key Points: The incidence of incisional hernia (IH) after live donor nephrectomy (LDN) is prevalent and associated with obesity and operative technique. Placing the hand port infraumbilical with a transverse fascial incision may reduce the risk of IH after LDN. Background: Characteristics of incisional hernia (IH) formation after live donor nephrectomy (LDN) are not well-defined. The goal of this study was to describe the incidence of IH within 3 years after LDN and identify risk factors contributing to their formation. Methods: We performed a single-center, retrospective review of all LDN between February 2013 and October 2018. Patients with and without IH were compared based on donor and operative variables. Data were analyzed using chi-square tests with column proportions. Multivariable logistic regression with backward elimination was used to evaluate the likelihood of IH on the basis of potential risk factors. Results: Three hundred one individuals underwent live donor nephrectomy. Twenty-eight patients (9.3%) developed an IH, with a median time to development of 7 months (range: 2–24 months). Obesity (body mass index ≥30), periumbilical hand port, and vertical infraumbilical hand port were associated with increased risk of IH development on univariate analysis. On multivariate analysis, obesity and periumbilical hand port location were persistent risk factors for IH. Conclusions: The incidence of IH after LDN is prevalent and associated with obesity and operative technique. Placing the hand port infraumbilical with a transverse fascial incision may reduce the risk of IH after LDN.